Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease
- PMID: 12642011
- DOI: 10.1007/s11906-003-0068-z
Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease
Abstract
Recent preclinical and clinical studies indicate that aldosterone, independent of angiotensin II and elevated blood pressure, may play a role in health and disease. In addition to its role in fluid and electrolyte balance and circulatory homeostasis, more recent studies have identified aldosterone as a critical mediator of vascular damage. In animal studies, aldosterone is implicated in cardiac and vascular fibrosis, renal disease, and cerebrovascular damage. These lesions are prevented by specific aldosterone receptor blockade. In clinical studies, aldosterone receptor antagonism is associated with decreased hospitalization, symptomatology, and mortality, and improvement of endothelial dysfunction in patients with chronic heart failure. A better understanding of aldosterone's actions in nonepithelial tissues should pave the way to better protection of organs at risk such as the kidneys, heart, and brain.
Similar articles
-
Aldosterone as a mediator in cardiovascular injury.Cardiol Rev. 2002 Mar-Apr;10(2):97-107. doi: 10.1097/00045415-200203000-00008. Cardiol Rev. 2002. PMID: 11895576 Review.
-
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.Ann Intern Med. 2009 Jun 2;150(11):776-83. doi: 10.7326/0003-4819-150-11-200906020-00005. Ann Intern Med. 2009. PMID: 19487712 Free PMC article. Review.
-
Effect of aldosterone and MR blockade on the brain and the kidney.Heart Fail Rev. 2005 Jan;10(1):53-62. doi: 10.1007/s10741-005-2349-x. Heart Fail Rev. 2005. PMID: 15947892 Review.
-
Review of aldosterone- and angiotensin II-induced target organ damage and prevention.Cardiovasc Res. 2004 Mar 1;61(4):663-70. doi: 10.1016/j.cardiores.2003.11.037. Cardiovasc Res. 2004. PMID: 14985063 Review.
-
Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.Curr Hypertens Rep. 2017 May;19(5):40. doi: 10.1007/s11906-017-0737-y. Curr Hypertens Rep. 2017. PMID: 28451852 Review.
Cited by
-
Diastolic heart failure in the elderly and the potential role of aldosterone antagonists.Drugs Aging. 2006;23(4):299-308. doi: 10.2165/00002512-200623040-00003. Drugs Aging. 2006. PMID: 16732689 Review.
-
Adrenocortical hypertension.Curr Hypertens Rep. 2004 Jun;6(3):224-9. doi: 10.1007/s11906-004-0073-x. Curr Hypertens Rep. 2004. PMID: 15128476 Review.
-
Proinflammatory/profibrotic effects of aldosterone in Gitelman's syndrome, a human model opposite to hypertension.J Endocrinol Invest. 2019 May;42(5):521-526. doi: 10.1007/s40618-018-0942-9. Epub 2018 Aug 22. J Endocrinol Invest. 2019. PMID: 30136149
-
Adrenocortical hypertension.Curr Urol Rep. 2006 Jan;7(1):73-9. doi: 10.1007/s11934-006-0045-6. Curr Urol Rep. 2006. PMID: 16480676
-
Blunted DOCA/high salt induced albuminuria and renal tubulointerstitial damage in gene-targeted mice lacking SGK1.J Mol Med (Berl). 2006 Sep;84(9):737-46. doi: 10.1007/s00109-006-0082-0. Epub 2006 Aug 10. J Mol Med (Berl). 2006. PMID: 16924469
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical